SCHEMBL14474674

SCHEMBL14474674

CNc1nc(-c2ccccn2)nc2c(OC)cc(-c3cccc(F)c3F)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.43
▸ LMNA P02545 4/20 0.43
▸ KDM4E B2RXH2 4/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ HSD17B10 Q99714 3/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ CYP2D6 P10635 2/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ FFAR1 O14842 2/20 0.42
▸ ABCB1 P08183 2/20 0.41
▸ ABCG2 Q9UNQ0 2/20 0.41
▸ METAP2 P50579 1/20 0.39
▸ METAP1 P53582 1/20 0.39
▸ TRPM8 Q7Z2W7 4/20 0.39
▸ MAPT P10636 3/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16185123 0.93 LMNA (0.46) SMN1; SMN2LMNAKDM4EALDH1A1HSD17B10
SCHEMBL14474689 0.91 FFAR1 (0.43) SMN1; SMN2LMNAKDM4EFFAR1METAP2
SCHEMBL14474681 0.90 CYP1A2 (0.41) SMN1; SMN2LMNAKDM4EALDH1A1HSD17B10
SCHEMBL14474673 0.89 LMNA (0.38) SMN1; SMN2LMNAKDM4EALDH1A1HSD17B10
SCHEMBL14474676 0.89 SCN9A (0.43) SMN1; SMN2LMNAKDM4EALDH1A1HSD17B10
SCHEMBL14474680 0.88 LMNA (0.38) SMN1; SMN2LMNAKDM4EALDH1A1HSD17B10
SCHEMBL16185151 0.86 L3MBTL1 (0.45) SMN1; SMN2LMNAKDM4EALDH1A1HSD17B10
SCHEMBL14474671 0.86 L3MBTL1 (0.47) SMN1; SMN2LMNAKDM4EALDH1A1HSD17B10
SCHEMBL14474182 0.85 ABCB1 (0.47) SMN1; SMN2LMNAKDM4EALDH1A1HSD17B10
SCHEMBL14474188 0.85 ABCB1 (0.47) SMN1; SMN2LMNAKDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
WO-2013003586-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB SMN1; SMN2 3987/4885LMNA 4832/4885KDM4E 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback